ChiCTR2500106093 版本V1.0 版本创建时间2025/07/17 10:41:35 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500106093 

最近更新日期:

Date of Last Refreshed on:

2025-07-17 10:41:24 

注册时间:

Date of Registration:

2025-07-17 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于 CRISPR 的肾移植术后 BK 病毒和 JC 病毒感染检测方法的建立及应用研究

Public title:

Establishment and application of CRISPR-based detection method for BK virus and JC virus infection after renal transplantation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于 CRISPR 的肾移植术后 BK 病毒和 JC 病毒感染检测方法的建立及应用研究

Scientific title:

Establishment and application of CRISPR-based detection method for BK virus and JC virus infection after renal transplantation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

汪骅 

研究负责人:

汪骅 

Applicant:

Hua Wang 

Study leader:

Hua Wang 

申请注册联系人电话:

Applicant telephone:

+86 189 1609 1096

研究负责人电话:

Study leader's telephone:

+86 189 1609 1096

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

fdeduwh@126.com

研究负责人电子邮件:

Study leader's E-mail:

fdeduwh@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市浦东新区浦建路160号

研究负责人通讯地址:

上海市浦东新区浦建路160号

Applicant address:

160 Pujian Road, Pudong New District, Shanghai, China

Study leader's address:

160 Pujian Road, Pudong New District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学医学院附属仁济医院

Applicant's institution:

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

研究负责人所在单位:

上海交通大学医学院附属仁济医院

Affiliation of the Leader:

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LY2025-224-B

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海交通大学医学院附属仁济医院伦理委员会

Name of the ethic committee:

Shanghai Jiaotong University School of Medicine, Renji Hospital Ethics Committtee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-07-14 00:00:00

伦理委员会联系人:

陆麟

Contact Name of the ethic committee:

Lin Lu

伦理委员会联系地址:

上海浦东新区浦建路160号

Contact Address of the ethic committee:

160 Pujian Road, Pudong New District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 6838 3364

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学医学院附属仁济医院

Primary sponsor:

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

研究实施负责(组长)单位地址:

上海市浦东新区浦建路160号

Primary sponsor's address:

160 Pujian Road, Pudong New District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属仁济医院

具体地址:

浦东新区浦建路160号

Institution
hospital:

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Address:

160 Pujian Road, Pudong New District

经费或物资来源:

上海交通大学医学院附属仁济医院培育基金连续资助项目 (RJPY-10-005)

Source(s) of funding:

Incubation Fund Continuous Funding Programs of Renji Hospital, School of Medicine, Shanghai Jiao Tong University (RJPY-10-005)

Target disease:

BK and JC virus infections

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

建立基于 CRISPR 的肾移植术后 BK 病毒和 JC 病毒感染检测方法。  

Objectives of Study:

To establish a CRISPR-based assay for detection of BK virus and JC virus infection after renal transplantation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

肾移植组: 1. 年龄≥18岁,性别不限; 2. 肾移植术后患者; 3. 在术后接受常规 BKV 或 JCV 病毒监测(如 qPCR); 4. 有完整的临床资料,包括手术记录、用药信息、实验室检测等。 健康对照组: 1. 无肾移植史,且无 BKV和JCV 感染高危因素; 2. 18 岁及以上。

Inclusion criteria

Kidney transplantation group: 1. >= 18 years; 2. Post renal transplant patients; 3. Reciving routine BKV or JCV monitoring (qPCR) after surgery; 4. Complete clinical information is available, including surgical records, medication information, and laboratory tests. Healthy control group: 1. No history of renal transplantation and no risk factors for BKV and JCV infection. 2. >= 18 years.

排除标准:

1. 同时患有其他严重病毒性感染(如 EBV、CMV 活跃感染)影响判断者; 2. 其他器官移植史; 3. 严重合并症(慢性病、恶性肿瘤)。

Exclusion criteria:

1. Patients with concurrent other serious viral infections (e.g., EBV, CMV active infection) that interfere with judgment; 2. History of other organ transplants; 3. Severe comorbidities (chronic diseases, malignant tumors).

研究实施时间:

Study execute time:

From 2024-01-01 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-01-01 00:00:00 To 2025-05-31 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

qPCR

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

qPCR

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

基于CRISPR的检测平台

Index test:

CRISPR-based detection platform

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

1. 肾移植术后患者; 2. 健康人群。

例数:

Sample size:

125

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

1. Post-kidney transplant patients; 2. Healthy population.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

N/A

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海交通大学医学院附属仁济医院 

单位级别:

三甲 

Institution
hospital:

Renji hospital, School of medicine, Shanghai Jiaotong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

敏感性

指标类型:

主要指标

Outcome:

sensitivity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

特异性

指标类型:

主要指标

Outcome:

specificity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

一致性

指标类型:

主要指标

Outcome:

consistency

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

相关性

指标类型:

主要指标

Outcome:

correlation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血浆

组织:

Sample Name:

Plasma

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not Applicable

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

拟于2025年9月于国家生物信息中心(https://ngdc.cncb.ac.cn/gsub/)共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data to be shared at the National Center for Biological Information (https://ngdc.cncb.ac.cn/gsub/) in September 2025.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

先由病例记录表(CRF)采集原始数据,再录入电子采集和管理系统(EDC)进行管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The original data were collected by the case record form (CRF), and then entered into the electronic collection and management system (EDC) for management.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-07-17 10:41:24